FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. PMID 36681013 · ESMO Open · 2023-Feb 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Early nutritional intervention does not prevent long-term adverse events in women with breast cancer: A pilot study. PMID 36657923 · Clin Nutr ESPEN · 2023-Feb The study is a randomized controlled trial in oncology with a drug intervention, but it is not a Phase III/IIIb or Phase II/III trial (it is a pilot study, and the phase is not explicitly established as definitive). Furthermore, the primary endpoint is chemotherapy toxicity (an adverse event), not a time-to-event efficacy endpoint like OS, PFS, or DFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors. PMID 36644853 · Expert Rev Gastroenterol Hepatol · 2023-Feb The record is a review/drug profile article that summarizes existing clinical trial evidence, not an original formal result report of a Phase III randomized trial. While it references Phase III trials (INVICTUS, INTRIGUE), the abstract does not present primary or key secondary time-to-event efficacy data. It is excluded as a review/meta-analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. PMID 36625894 · Cancer Chemother Pharmacol · 2023-Feb The record describes an exposure-response analysis, which is a secondary/pharmacometric analysis, not the primary or definitive efficacy report of the CheckMate 9ER trial. While the trial is Phase III, oncology, human, involves drug intervention, and includes time-to-event endpoints, the report type is secondary. Randomization is strongly implied but not explicitly stated in the provided abstract. Therefore, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. PMID 36623515 · Lancet Oncol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions. PMID 36622402 · Cancer Chemother Pharmacol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial. PMID 36621991 · J Urol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Protocol for a 4-arm randomized controlled trial testing remotely delivered exercise-only, diet-only, and exercise + diet interventions among men with prostate cancer treated with radical prostatectomy (Prostate 8-II). PMID 36621597 · Contemp Clin Trials · 2023-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study. PMID 36618900 · EClinicalMedicine · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial. PMID 36604262 · Nutr Metab Cardiovasc Dis · 2023-Feb The record describes a non-oncology (cardiovascular risk) randomized controlled trial of vitamin D supplementation. While it includes a pre-specified death outcome and cancer as part of a composite secondary endpoint, the primary endpoint is fracture (non-skeletal). The intervention is non-drug-only, and the trial phase is not specified as definitive (Phase III/IIIb or Phase II/III). Therefore, it does not meet the core eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. PMID 36592505 · Eur J Cancer · 2023-Feb The record is a sub-study of the ABCSG-12 trial, analyzing the effect of the number of zoledronate infusions. It is not the primary report of the parent Phase III randomized trial's results. The eligibility criteria require an 'original formal-result report' of a Phase III/IIIb or Phase II/III randomized trial. This sub-study, while derived from a randomized trial, is a secondary analysis and does not represent the primary trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial. PMID 36579790 · Cancer Commun (Lond) · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Findings from Children's Oncology Group (COG) study ARST0332. PMID 36566574 · Eur J Cancer · 2023-Feb This is a secondary analysis of a Phase III trial focusing on a specific subgroup (lymph node metastases). While the parent trial (ARST0332) is Phase III and randomized, this specific publication is a subgroup analysis, which is not eligible per the criteria to exclude post-hoc subgroup analyses. The deterministic review correctly identified unclear randomization evidence for this specific report, confirming it is not a primary report of a randomized comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. PMID 36564535 · Ann Hematol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Mindfulness-based stress reduction for men on active surveillance for prostate cancer and their spouses: Design and methodology of a randomized controlled trial. PMID 36563902 · Contemp Clin Trials · 2023-Feb This is a clinical trial protocol (design/methodology only) for a randomized trial in oncology (prostate cancer). It is not a result report. It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) and does not involve a drug-containing intervention (intervention is mindfulness-based stress reduction). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. PMID 36545810 · Cancer Commun (Lond) · 2023-Feb The record describes a phase III randomized trial of a drug intervention in oncology patients with an original result. However, the primary efficacy endpoint is complete response (a binary proportion), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR, which is required for eligibility. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. PMID 36529145 · Lancet Haematol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. PMID 36527976 · Eur J Cancer · 2023-Feb The study is a retrospective, non-randomized real-world comparison, not a prospective randomized Phase II/III or Phase III trial, which is required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase III results for first-line treatment for metastatic colorectal cancer. PMID 36526904 · Nat Rev Gastroenterol Hepatol · 2023-Feb The record describes an oncology, human, randomized, Phase III trial with a drug intervention and appears to be an original results report. However, the metadata contains no explicit signal of a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.), which is a required criterion for inclusion. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial. PMID 36525180 · Breast Cancer Res Treat · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. PMID 36521500 · Lancet Gastroenterol Hepatol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. PMID 36517990 · Leuk Lymphoma · 2023-Feb The study is an oncology randomized controlled trial with drug intervention and phase II/III, but the provided metadata does not explicitly state a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, KM). Without this signal, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Plasma anthocyanins and their metabolites reduce in vitro migration of pancreatic cancer cells, PANC-1, in a FAK- and NF-kB dependent manner: Results from the ATTACH-study a randomized, controlled, crossover trial in healthy subjects. PMID 36516693 · Biomed Pharmacother · 2023-Feb The record is a randomized, controlled trial in healthy subjects investigating the effect of an anthocyanin-rich juice on pancreatic cancer cell migration in vitro. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention in cancer patients with a time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study. PMID 36512912 · Gynecol Oncol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effects on heavy menstrual bleeding and pregnancy of uterine artery embolization (UAE) or myomectomy for women with uterine fibroids wishing to avoid hysterectomy: The FEMME randomized controlled trial. PMID 36511801 · Int J Gynaecol Obstet · 2023-Feb The study is excluded because it is not an oncology trial. It investigates treatments for uterine fibroids (benign) and does not involve a drug-containing intervention for malignant neoplasms. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts. PMID 36496303 · Lancet Digit Health · 2023-Feb The record is an original result report from randomized trials but does not involve a drug-containing intervention as the primary comparison; it is a secondary analysis combining data for molecular classification and prognostication. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Validation of the Lee-Jones theoretical model of fear of cancer recurrence among breast cancer survivors using a structural equation modeling approach. PMID 36468339 · Psychooncology · 2023-Feb The record is an oncology, human, randomized, original-result report. However, it is excluded because it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) and does not involve a drug-containing intervention (the intervention is a psychosocial/online intervention). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. PMID 36464853 · Cancer Med · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. PMID 36423745 · Ann Oncol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial. PMID 36422763 · Front Med · 2023-Feb The record describes a randomized trial of adjuvant chemotherapy vs. concurrent chemoradiotherapy in cervical cancer, with PFS as the primary endpoint and HR reporting. However, the trial phase is not explicitly stated as Phase III, Phase II/III, or equivalent in the provided metadata, which is required for eligibility. All other criteria are met. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. PMID 36400384 · Ann Oncol · 2023-Feb 命中用户提供的消化道肿瘤阳性参考集。 |
B
|
影子组漏检补回 | eligiblepositive_reference | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Effectiveness of mind-body exercise via Baduanjin on physical and psychological outcomes in patients with pulmonary ground-glass nodules: A non-randomized controlled pilot study. PMID 36399997 · Complement Ther Clin Pract · 2023-Feb The study is a non-randomized, controlled pilot trial (explicitly stated as 'non-randomized controlled pilot study') in oncology patients, which fails the randomized criterion. It is not a Phase III/IIIb or Phase II/III trial. The intervention is a mind-body exercise (Baduanjin), not a drug-containing intervention. The primary and secondary outcomes (pulmonary function, psychological condition, quality of life) are not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Multi-centre, Single Arm, Non-randomized, Prospective European Trial to Evaluate the Safety and Efficacy of the HistoSonics System in the Treatment of Primary and Metastatic Liver Cancers (#HOPE4LIVER). PMID 36380155 · Cardiovasc Intervent Radiol · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term follow-up of a randomized trial of biliary drainage in perihilar cholangiocarcinoma. PMID 36376222 · HPB (Oxford) · 2023-Feb 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors. PMID 36376169 · Clin Genitourin Cancer · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. PMID 36369793 · Arthritis Rheumatol · 2023-Feb The study is a randomized, placebo-controlled Phase III trial evaluating the long-term safety and tolerability of anifrolumab in patients with systemic lupus erythematosus (SLE), which is an autoimmune disease, not a human malignant neoplasm (oncology). It does not have a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or HR from Kaplan-Meier analysis). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. PMID 36334968 · Eur Urol · 2023-Feb The record describes a randomized screening trial for prostate cancer with a time-to-event primary endpoint (PC mortality). However, the intervention is PSA screening, not a drug-containing intervention. Therefore, it does not meet the 'drug_intervention' criterion required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. PMID 36331676 · Invest New Drugs · 2023-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Early Intensive Blood Pressure Management After Thrombectomy: Protocol for a Randomized Controlled Clinical Trial (IDENTIFY). PMID 36329307 · Neurocrit Care · 2023-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cerebral Protection of Intraoperative Infusion of Dexmedetomidine in Patients with Chronic Cerebrovascular Stenosis Undergoing Endovascular Interventional Therapies: A Prospective Randomized Controlled Trial. PMID 36309168 · Ann Vasc Surg · 2023-Feb The study is a randomized trial of a drug (dexmedetomidine) but is not an oncology trial. It investigates a neuroprotective effect in patients with cerebrovascular stenosis undergoing endovascular intervention, with endpoints focused on biomarkers, cognitive function scores, and hemodynamic indexes. No time-to-event efficacy endpoint (OS, PFS, DFS, etc.) is reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Functional evaluation of a spiral neobladder with an angled chimney; A prospective randomized comparative study. PMID 36244843 · Eur J Surg Oncol · 2023-Feb The study is an original randomized trial in human bladder cancer patients, but it compares surgical techniques (neobladder chimney positions) and does not involve a drug-containing intervention. It reports functional/surgical outcomes (complications, reflux) without a time-to-event efficacy endpoint like OS, PFS, or Kaplan-Meier analysis. Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. PMID 36216134 · J Hepatol · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. PMID 36168187 · Cancer Med · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer. PMID 36156460 · Cancer Med · 2023-Feb The record is eligible for inclusion in the cohort only if it is an original formal-result report of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. This record fails on multiple criteria: 1) It is not an original result report of a single trial; it is a secondary analysis/study of many trials from ClinicalTrials.gov. 2) It does not present any time-to-event efficacy data (Kaplan-Meier curves, HR, OS, PFS, etc.) for a drug intervention. 3) The publication types and abstract describe the study's own design (phase 3 trials investigation) but it does not report the efficacy results of those trials. Therefore, it is not eligible. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ablation versus resection for resectable colorectal liver metastases - Health care related cost and survival analyses from a quasi-randomised study. PMID 36123245 · Eur J Surg Oncol · 2023-Feb The record does not meet eligibility criteria. The study is quasi-randomized, not truly randomized, and compares procedural interventions (ablation vs. resection) without a drug-containing arm. Therefore, it is excluded despite being an oncology study with human subjects, original results, and a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic nomogram in patients with epithelioid sarcoma: A SEER-based study. PMID 36073670 · Cancer Med · 2023-Feb The record is a prognostic model development study using SEER registry data for epithelioid sarcoma. It does not involve a drug-containing intervention, is not a Phase III or definitive Phase II/III randomized trial of a therapy, and thus fails key eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Death Anxiety and Correlates in Cancer Patients Receiving Palliative Care. PMID 36067074 · J Palliat Med · 2023-Feb The study is an ancillary analysis of a randomized clinical trial of Dignity Therapy (a psychosocial intervention) in cancer patients receiving palliative care. It is not a drug intervention trial, lacks a definitive Phase III designation, and does not report a primary time-to-event efficacy endpoint such as overall survival or progression-free survival. Therefore, it does not meet the inclusion criteria for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Intratumoral and peritumoral radiomics nomograms for the preoperative prediction of lymphovascular invasion and overall survival in non-small cell lung cancer. PMID 36064979 · Eur Radiol · 2023-Feb The study is a retrospective radiomics analysis for prognosis prediction in NSCLC, not a randomized Phase III/IIIb or Phase II/III therapeutic trial with a drug intervention. It lacks the required trial phase and drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Operating on Anxiety: Negative Affect toward Breast Cancer and Choosing Contralateral Prophylactic Mastectomy. PMID 36059240 · Med Decis Making · 2023-Feb This is a randomized behavioral science study on affect and treatment choice in healthy women, not a clinical trial of a drug intervention in cancer patients with time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. PMID 36058804 · Eur Urol · 2023-Feb The record describes a randomized trial in human oncology with a time-to-event primary endpoint (recurrence-free survival). However, it does not meet two key eligibility criteria: (1) the intervention is non-drug (laser vs. surgical procedure), and (2) the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |